PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Menopausal disorders (Estradiol with levonorgestrel - Menopausal disorders)

Records returned : 25 (on 25 Nov 2024 at 09:07:02). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Estradiol with levonorgestrel
Menopausal disorders
Green (see narrative)
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Femseven Conti patches - less preferred. Only use in the event of product shortages.
06.04.01
Tibolone
Menopausal disorders
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe generically
06.04.01
07.02.01
Estradiol
Menopausal disorders
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Elleste Solo tablets - 1st line
06.04.01
07.02.01
Menopausal disorders
Green
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven, Progynova TS)
06.04.01
07.02.01
Menopausal disorders
Green
Formulations :
  • Spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Lenzetto spray. Caution with higher than licensed doses.
Estradiol with dydrogesterone
Menopausal disorders
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Femoston tablets - 1st line for women requiring sequential combined therapy.
Estradiol with progesterone
Menopausal disorders
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Bijuve capsules - 1st line for women requiring continuous combined therapy.
Estradiol with dydrogesterone
Menopausal disorders
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Femoston Conti - 1st line for women requiring continuous combined therapy.
Estradiol with norethisterone
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Elleste Duet Conti - 2nd line for women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line).
Menopausal disorders
Green (see narrative)
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Evorel Conti patches - preferred in women with risk factors for VTE or migraine. Otherwise use a 1st-line oral option.
Menopausal disorders
Green (see narrative)
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Evorel Sequi patches 2nd-line. Preferred option in women with risk factors for VTE or migraine.
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Elleste Duet tablets 2nd line. For women requiring sequential combined therapy but with poor cycle control on Femoston (1st-line).
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Novofem tablets - Only use if there are product shortages with Elleste Duet
06.04.01
07.02.01
Estradiol
Menopausal disorders
Green (see narrative)
Formulations :
  • Gel
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Oestrogel is the preferred gel option. Sandrena is an alternative option.
06.04.01
Progesterone
Menopausal disorders
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Prescribe generically. Micronised progesterone oral capsules.
Estradiol with norethisterone
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Kliofem tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Kliovance tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
06.04.01
07.02.01
Estradiol
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.
06.04.01
07.03.02
Medroxyprogesterone acetate
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
10mg tablets for adjunctive progestogen therapy
2nd line for endometrial protection in women who have abnormal bleeding on other HRT.
Drospirenone
Menopausal disorders
N/A
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
Un
Estradiol with medroxyprogesterone
Menopausal disorders
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Indivina tablets - consider changing to a newer, 1st or 2nd line option.
Conjugated oestrogens
Menopausal disorders
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Recommend switching to a newer, lower risk formulation.
Estradiol with norethisterone
Menopausal disorders
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Trisequens tablets - consider changing to newer, 1st or 2nd line options.
Estradiol with medroxyprogesterone
Menopausal disorders
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Tridestra tablets - consider changing to a newer, 1st or 2nd line option.
Conjugated oestrogens with medroxyprogesterone
Menopausal disorders
Non Formulary
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Premique Low Dose - no longer recommended. Switch to a newer, lower risk formulation.
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More